Dalrada Accelerates Its National Healthcare Model With Acquisition of Watson Rx Solutions

SAN DIEGO–(BUSINESS WIRE)–$DFCO #DFCO—Dalrada Corporation (OTCQB: DFCO, “Dalrada”) announced today that it had acquired the pharmacy, Watson Rx Solutions, Inc. The move highlights Dalrada’s aggressive growth plans within the healthcare sector and paves the way for a total end-to-end total healthcare solution.

Adding the 10-year-old pharmacy to Dalrada Health’s comprehensive model expands the subsidiary’s synergies with potential opportunities across its products and services portfolio and offers another solution to meet patient requirements.

Dalrada envisions a comprehensive healthcare solution for all Dalrada Health clients with unique offerings that will now include: a pharmacy to facilitate prescription processing, physicians and clinicians at treatment clinics, expanding into telemedicine, engagement of Dalrada-owned testing facilities and laboratories, and utilization of Company-specific technologies to facilitate immediate growth of the business.

CEO and Founder, Brian Bonar, states, “Watson Rx has a long history of providing excellent pharmacy services. This acquisition allows Dalrada to expand its healthcare footprint and continue to build a total health management solution on an already successful turnkey operation. As a result, the Company will be able to successfully address the health needs of even more patients.”

Through comprehensive prescription management, education, nursing, and total health management, Watson Rx Solutions’ leadership team holds more than six decades of combined experience in various complex pharmacy disease states and retail services, always putting patients first.

Dalrada plans on entering the pharmaceutical space with an accelerated strategic plan to leverage the Company’s existing capabilities. Research reveals that the U.S. online and mail-order sales of drugs, health, and beauty aids were valued at 75.5 billion USD in 2020. Additionally,

• E-commerce pharmaceutical sales and beauty aids increased from 51.7 billion USD the year prior.
• Online, E-commerce, and mail-order sales increased from around 31 to 38 percent during the same period.

Pharmacy and drug store sales reached 300 billion USD in 2020, with over-the-counter (OTC) medication accounting for over 36 billion USD in sales during the same year, the highest-selling year to date for the OTC segment. (Source: Statista U.S. online and mail-order sales of drugs, health and beauty aids, 2003-2020).

Dalrada and its subsidiaries provide value by making timely and impactful products and services available within health, technology, and clean energy markets. To learn more about how Dalrada Corporation continuously creates innovative solutions to address the complex challenges of today and the future, please visit www.Dalrada.com and www.DalradaHealth.com.

About Dalrada:

Dalrada Corporation drives innovation that positively impacts people, businesses, and the planet. With subsidiaries that are firmly positioned in the world’s top three-growing industries of healthcare, clean energy, and technology, Dalrada creates solutions that are sustainable, affordable, and accessible.

The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada’s global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.

Established in 1982, Dalrada has since grown its footprint to include the unique business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies. For more information, please visit www.dalrada.com, and follow us on Twitter, Facebook, and LinkedIn.

Disclaimer:

Statements in this press release that are not historical facts, the statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations regarding these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the US Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.

Contacts

Denise Mahaffey

858.283.1253

inquiries@dalrada.com